6th ICHNO Abstract Book

page 62 6 th ICHNO Conference International Conference on innovative approaches in Head and Neck Oncology 16 – 18 March 2017 Barcelona, Spain __________________________________________________________________________________________ 6th ICHNO

and Dmax of IC and MDADI Score at 6 months; There’s correlation between V30, V50, V60, V66, V70, Mean doses of SGL and the PSSN Score at 6 months. For MDADI scores, there’s a positive relationship of V30, V50, V60, V66, V70 and Mean of SGL and 6 month MDADI score.There is no significant correlation between doses to GL and CE and Scores. There is a high rate of baseline aspiration on objective testing with Modified Barium Swallow. In the brachytherapy group, D mean and D max and various V d’s of the DARS were significantly lower than in the EBRT alone group. This dosimetric analysis demonstrated that brachytherapy can significantly reduce dose to DARS. But more prospective trials are required to study swallowing outcomes post Brachytherapy. Conclusion The findings of this study motivate further efforts beyond IMRT to reduce the dose to the swallowing structures when planning chemoradiotherapy for locally advanced head- and-neck squamous cell carcinoma in cases where the planning target volume does not overlap with DARS. Use of Brachytherapy as a boost could spare significant dose to the pharyngeal constrictors in such cases post External Radiotherapy. PO-129 managing the consequences of head and neck in radiotherapy a Radiotherapy Late Effects clinic J. Christian 1 , E. Stones 2 , E. Hallam 2 1 Nottingham University Hospital- Nottingham, Department of Clinical Oncology, Nottingham, United Kingdom 2 Nottingham University Hospital, Department of Radiotherapy, Nottingham, United Kingdom Purpose or Objective Due to the rising number of patients’ now surviving head and neck cancer, there are increasing number of patients living with the long-term consequences of treatment. Since October 2014, our hospital has run a fully comprehensive Radiotherapy Late Effects (RTLE) programme for all patients who are disease free but suffering with the adverse late effects of their radiotherapy treatment. At the centre of the programme is an open access clinic, where patients can self-refer. From there, patients can be given information about managing their RTLE. For those with more severe symptoms we have developed clinical pathways now accessing a vast array of specialist interest clinical teams within the hospital. This study assesses the patients attending the RTLE clinic who have previously been treated for Head and Neck cancer Material and Methods The database was reviewed for all patients who have attending the RTLE clinic. Details of tumour location, treatment details, time since treatment were recorded alongside patient quality of life measures using a simple modified Holistic Needs Assessment (HNA) tool that identifies people’s concerns and needs from a score of 1 – 10, where 1 represents the lowest level of concerns and 10, the highest. Patients were seen in the clinic by therapy radiographers, their symptoms and difficulties discussed and HNA carried out. Depending on the symptoms and the severity of the presentation, patients were either given information sheets pertinent to their specific late-effects or would be advised to access one of the specialist pathways. HNA was carried out at presentation to the clinic and then at approximately 6 months later. Patients were required to have completed RT more than 6 months prior to referral. Results From October 2014 – Sept 2016, 153 patients have been seen the RTLE clinic. Of these, 45 patients had previously been treated for Head and Neck cancer with a radical

dose. This group was larger than the prostate cancer patient group within the clinic. 35.7% had received treatment for oropharynx cancer, 28.6% for tongue cancer, 14.3% for hypopharyngeal/larynx cancer. 39 patients had follow-up data available. Median time from end of radiotherapy to clinic referral was (2.52 years). Range 5.6 months – 30 years. 16/39 (41.0%) patients were given general advice and information only. 23/39 (59.0%) needed referral to a specialist team as described in Table 1. A total of 28 specialist team referrals were made, some patients requiring more than one referral. Only 6 of the 28 referrals required going back into specialist medical clinics. The mean HNA score at initial presentation was 7.28 and at follow-up the mean score had reduced to 4.72.

Table 1 Outcomes of the Radiotherapy Late Effects clinic

Conclusion A RTLE clinic can provide an excellent support for people suffering the consequences of the Head and Neck cancer treatment. Giving advice and signposting patients to the correct clinical pathways can reduce patients concerns and provide a cost-effective management strategy that does not necessarily involve medical appointments. PO-130 Longitudinal assessment of enteral nutrition requirement in 1st line treatment of SCCHN M.N. Falewee (France), C. Michel, C. Hebert, E. Chamorey 1 Centre Antoine Lacassagne, Nutrition, NICE, France 2 Centre Antoine Lacassagne, Medical Writing, Nice, France 3 Centre Antoine Lacassagne, Medical Oncology, Nice, France 4 Centre Antoine Lacassagne, Biostatistics, Nice, France Purpose or Objective First line SCCHN patients can be treated by: surgery (S), radiotherapy (RT), chemotherapy (C), radiochemotherapy (RTCT), induction chemotherapy ± RTCT (IND), surgery + RT, surgery + RTCT. There is a lack of prospective data regarding nutritional support necessity whatever treatment realized. Material and Methods This was a prospective study conducted in a single institution from December 2012 to December 2014. The aim was to evaluate enteral nutrition importance (rate, length and occurrence) and outcomes over the first 18 months of treatment. Results Hundred and thirty-five patients have been enrolled: 22 in the S group, 16 in the RT group, 3 in the CT group, 28 in the RTCT group, 31 in the IND group, 11 in the surgery + RT group, 23 in the surgery + RTCT group. EN was set up before treatment in 11.8% of patients and the mean EN length (SD) during this period was 20.4 (16.2) days. From treatment start to 18 months after, 67.4% of patients beneficiated from EN. The mean time (SD) of first support set up was 73.3 (87.2) days. The total EN mean length (SD) during the period was 133.7 (137.5). During the post treatment period, EN was set up one time in 57 patients